Crinetics, Jefferies

Jefferies Upgrades Crinetics Pharmaceuticals (CRNX)
Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from Hold to Buy. Analyst Price Forecast Suggests 94.74% Upside As of December 23,
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other Billionaire Joseph Edelman’s long-term stock picks.
Crinetics upgraded to Buy from Hold at Jefferies
Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in
Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns “Buy” Rating from HC Wainwright
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $81.
How Does Crinetics Pharmaceuticals Inc (CRNX) Stack Up Against Its Industry Peers?
Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and touched a low of $40.
Crinetics upgraded to buy by Jefferies, atumelnant potential cited
Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the treatment of congenital adrenal hyperplasia,
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation ...
Crinetics Pharmaceuticals: Promising Phase 2 Results and Strong Growth Potential Lead to Buy Rating
Analyst David Lebowitz from Citi maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) and keeping the price target at ...
Seeking Alpha20d
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for ...
Yahoo Finance17d
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will ...
CNN4y
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases ...
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.